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Cost-effectiveness analysis and budgetary impact of the 
Cryptococcal Antigen Lateral Flow Assay (CRAG-LFA) 
implementation for the screening and diagnosis of 
cryptococcosis in asymptomatic people living with HIV in Brazil 
Cid Manso de Mello Vianna 1, Gabriela Bittencourt Gonzalez Mosegui 2 
ABSTRACT 
Cryptococcal infection is a frequent cause of mortality in Brazilian HIV-infected 
patients. The present study aimed to evaluate the cost-effectiveness and budgetary impact 
of four cryptococcosis screening strategies in HIV-infected patients with CD4+ ≤ 200 
cells/mm³, in Brazil. A Monte Carlo microsimulation was used to compare the following 
diagnostic tests: a systematic serum cryptococcal antigen (CRAG) screening with latex 
agglutination (CRAG-LA), a lateral flow immunochromatographic test (CRAG-LFA), 
India ink staining and no intervention. The rationale was that of the Unified Health System 
(SUS), and the time horizon was of one year for the intervention and of five years for 
the budgetary impact analysis (BIA). The effectiveness outcomes were years of life and 
years of life adjusted for quality (QALY). The cost-effectiveness analysis showed that 
the two cryptococcal antigen tests were cost-effective, presenting with superior results in 
comparison with India ink and no screening. CRAG-LFA, compared to CRAG-LA, has 
an incremental cost of US$0.25 and an incremental cost-effectiveness ratio of US$73.36 
(considering the US dollar equal to 5 reais, the Brazilian current money). The probabilistic 
sensitivity analysis between CRAG-LFA and CRAG-LA, despite showing a high agreement 
between the two tests, indicated the superiority of CRAG-LFA. The BIA estimated that the 
incorporation of CRAG-LFA would have an additional cost of approximately U$S 10.4 
million dollars in five years. These findings suggest that, for the group of studied patients, 
the adoption of CRAG-LFA and CRAG-LA are cost-effective, while the India ink test and 
no intervention are less effective strategies. The BIA showed that using the CRAG-LFA 
test for people living with HIV (PLHIV) with CD4+ ≤ 200 cells/mm3 could reduce costs 
for the Brazilian Unified Health System (SUS).
KEYWORDS: Cost-benefit analysis. Diagnostic test approval. Cryptococcus. HIV infections. 
INTRODUCTION
Cryptococcosis is a systemic mycosis caused by fungi of the genus Cryptococcus. 
The infection typically affects the central nervous system (CNS) and the respiratory 
tract, commonly presenting as cryptococcal meningitis (CM). HIV infection with a 
CD4 count below 200 cells/mm3 and the presence of the acquired immunodeficiency 
syndrome (AIDS) are predisposing conditions for cryptococcosis1.
CM is associated with about 15% of all HIV deaths. In 2014, a total of 
223,100 CM cases led to 181,100 deaths, 75% of which in sub-Saharan Africa, 
followed by Southeast Asia and Latin America2. In Brazil, the cryptococcosis 
mortality rate is between 45% to 65% regardless of HIV risk factors and the primary 
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form of the disease3. Cryptococcosis occurs as the first 
opportunistic manifestation in about 4.4% of AIDS cases in 
Brazil3,4. In addition, patients recovering from cryptococcal 
meningitis may experience long-term neurological and 
sensory impairment (≥ 3 months after the diagnosis), 
resulting in disability and poor quality of life5,6 a tertiary 
referral hospital to HIV-infected patients serving the São 
Paulo State, Brazil. All patients were >18 years old without 
prior cryptococcal meningitis, without clinical suspicion of 
cryptococcal meningitis, regardless of antiretroviral (ART.
The Unified Health System (SUS) provides different 
methods for diagnosing Cryptococcosis. The conventional 
one is the direct examination of slides stained with India 
ink and the sample’s culture on Sabouraud dextrose agar 
(SDA)4. In the case of Cryptococcosis, the India ink method 
refers to the direct microscopy of the cerebrospinal fluid 
(CSF), secretions or exudates, subcutaneous aspirate, 
pus, urine, serum, plasma or blood to visualize yeasts4. 
In contrast, the SDA culture consists of yeast culture for 
seven days, between 25 °C to 37 °C4. Serological techniques 
can be used to detect antigens (CRAG) or search for 
antibodies. The latex agglutination test (CRAG-LA) is 
one of the most frequently used due to its high accuracy4,7 
along with the lateral flow immunochromatographic test 
(LFA)8 the cryptococcal antigen lateral flow assay (CrAg 
LFA. The CRAG-LFA is a rapid diagnostic test that 
provides a definitive result in ≤ 10 min. with no need of 
specialized physical structure. The technique is stable at 
room temperature and easy to use and interpret results8 the 
cryptococcal antigen lateral flow assay (CrAg LFA.
The Brazilian Ministry of Health (MH) Clinical Protocol 
and Therapeutic Guideline (CPTG) for the treatment of 
adults with HIV recommends that people living with HIV 
(PLHIV) should to be investigated for fungal etiology in 
all pneumonia cases in addition to the routinely performed 
exams7. Those who are CRAG-positive and present with 
CD4 ≤ 100 cells/mm3 are subjected to preemptive treatment 
with fluconazole and antiretroviral therapy (ART) until 
they reach CD4 > 200 cells/mm³. The cost-effectiveness of 
CRAG screening, in either asymptomatic or symptomatic 
CM patients, has never been evaluated in Brazil. 
The primary aim of this study was to model the cost-
effectiveness and budget impact of implementing CRAG 
screening for asymptomatic cryptococcus infections in 
PLHIV with CD4+ ≤ 200 cells/mm3, in Brazil. 
MATERIALS AND METHODS
A Monte Carlo analytical decision model assessed 
the cost-effectiveness ratio and budgetary impact of the 
screening of PLHIV, over 18 years old, of both genders, 
infected with cryptococcosis, asymptomatic, with 
CD4  ≤  200 cells/mm3, using the following methods as 
screening strategies: (a) the point-of-care diagnostic test 
CRAG-LFA, (b) cryptococcus research in CSF with India 
ink or (c) CRAG-LA in serum, using no intervention as 
the baseline. Each strategy has its own accuracy value and 
employs different sample collection methods. This type 
of analysis records the patient’s history and the transition 
probabilities depend on the variables involved, allowing 
great clinical complexity in the development of the model. 
The perspective adopted considered the SUS as the 
funding agency for the services. The horizon for the cost-
effectiveness analysis was one year for the intervention, 
evaluating its impact on the disease’s development for five 
years, as many patients have life expectancies almost equal 
to those of people without HIV9. A discount rate of 3% per 
year was applied10.
The primary outcomes were years of life and quality-
adjusted life years (QALY)2,11. Estimates referring to direct 
medical costs included the identification, measurement and 
evaluation of the applied resources. A sensitivity analysis10 
assessed the uncertainties of the model.
According to the CPTG for the management of HIV 
infection in adults7, the screening and preemptive treatment 
strategy for cryptococcosis prevent deaths in individuals 
with ART CD4+ ≤ 100 cells/mm3. The document highlights 
patients without clinical manifestations of cryptococcosis 
but presenting with a test showing positive detection of 
cryptococcal antigenemia in CSF samples obtained by 
lumbar puncture (LP), performed to rule out CM. Then, 
a preemptive treatment with 800 mg fluconazole per day 
for two weeks and 400 mg fluconazole per day for eight 
weeks is prescribed and ART will be administered after the 
first two weeks of antifungal treatment4,7. All individuals 
with positive plasma or serum tests are investigated for 
CM using LP. The treatment of positive cases follow these 
phases: (a) induction, (b) consolidation and (c) maintenance, 
recommended by the Brazilian consensus and CPTG4,7. 
SUS’s reimbursement amounts for different items were 
used as measures of the abovementioned costs. Procedures 
and test values were obtained from the Ministry of Health12-14 
and, when not available, from the Brazilian Hierarchical 
Classification of Medical Procedures of the Brazilian 
Medical Association (BMA)15 in addition to several 
consultations of studies by Lofgren et al.16 implementation 
studies and evaluations of how to integrate CrAg screening 
programs into existing HIV care infrastructure are lacking. 
During a CrAg screening program in Kampala, Uganda, 
we interviewed 15 health care workers (2 coordinating 
research nurses and 13 clinic personnel and Rajasinghan 
et al.17 and CrAg positivity is an independent predictor of 
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meningitis and death. CrAg screening for patients with 
advanced HIV and preemptive treatment is recommended 
by the World Health Organization, though implementation 
remains limited. Our objective was to evaluate costs and 
mortality reduction (lives saved Table 1 shows the values 
adopted for the procedures and treatments.
Table 1 - Values of procedures, treatments, medications, and tests included in the economic model and other parameters of the model.
Procedures/Drugs/Treatment (the reference is no intervention) Costs (U$S) 
Medicines Concentration Unit cost Treatment cost Source
Fluconazole 150 mg 0.07 -
Brasil. Ministério da 
Saúde12 
Fluconazole 100 mg 3.14 -










Fluconazole 800 mg 2 6.56 92.00 
Brasil. Ministério da 
Saúde12
Fluconazole 400 mg 8 3.28 184.00 




Mycoses treatment (code 03.03.01.016-9) 2 23.27 325.72
Brasil. Ministério da 
Saúde13 
Consolidation phase
Fluconazole 600 mg/day 8 0.29 17.23
Brasil. Ministério da 
Saúde13 
Maintenance phase
Fluconazole 200 mg 48 6.28 2,293.66
Brasil. Ministério da 
Saúde12
Tests and culture Amount Unit cost Cost / patient Source
CRAG-LFA 1 6.00 6.00 Brasil14 
CRAG-LA
Cryptococcus research - latex (code 4.03.09.05-3) 1 0.36 0.36
Associação Médica 
Brasileira15 
Cryptococcus research – India ink (code 4.03.10.10-0) 1 0.14 0.14
Associação Médica 
Brasileira15
Culture for fungi identification (code 02.02.08.13-7) 1 0.84 0.84
Brasil. Ministério da 
Saúde13
Procedures Amount Unit cost Cost / patient Source
Collection of samples for laboratory examination (code 
02.01.02.004-1)
2 0 0
Brasil. Ministério da 
Saúde13
Specialized medical attention (code 03.01.01.007-2) 2 2.00 4.00
Brasil. Ministério da 
Saúde13
Individuals with CRAG-LA test, India´s ink (LP) 
Lumbar puncture (code 02.01.01.063-1) 1 1.41
Brasil. Ministério da 
Saúde13
Induction phase
Mycoses treatment (code 03.03.01.016-9) 2 23.27 325.72
Brasil. Ministério da 
Saúde13
Consolidation phase
Specialized medical attention (code 03.01.01.007-2) 2 2.00 4.00
Brasil. Ministério da 
Saúde13
Maintenance phase
CD4 Lymphocyte count (code 02.02.03.002-4) 2 3.00 6.00
Brasil. Ministério da 
Saúde13
Collection of samples for laboratory examination (code 
02.01.02.004-1)
2 0 0
Brasil. Ministério da 
Saúde13
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Procedures/Drugs/Treatment (the reference is no intervention) Costs (U$S) 
Specialized medical attention (code 03.01.01.007-2 -) 3 2.00 6.00
Brasil. Ministério da 
Saúde13
Parameters Probability (%) CI (95%) Distribution Source
Percentage of CD4 ≤ 100 in cryptococcosis 40 30–70 Rajasingham et al.17 
Percentage CD4 ≤ 200 cells/mm³ in cryptococcosis 60 30–70 Rajasingham et al.17 
Developed CM after preemptive treatment 14 Meya et al.19 
Diesd after preemptive treatment 29.1 Meya et al.19 
Developed CM after hospital treatment 8 0–20 Beta Meya et al.19
CRAG+ among those who developed CM 33 25–41 Beta Rajasingham et al.17 
CRAG+ among those who developed MC and died 40 34–46 Beta Rajasingham et al.17
CM progression in CRAG+ without preemptive treatment 70 56–82 Beta Rajasingham et al.17
Survived after hospital treatment 45 38–52 Beta Ramachandran et al.18 
Developed CM after hospital treatment 32 Ramachandran et al.18 
PLHIV CD4 ≤ 200 cells/mm³ CRAG+ asymptomatic with CM 2.3 Meya et al.19
PIHIV CD4 ≤ 100 cells/mm³ CRAG+ asymptomatic with CM 8.04 5.8–12.6 Beta
Morawski et al.21, Meya 
et al.19,
CM mortality (fatality ratio) 26–63 Vidal and Boulware8
Utility
Stable with HIV 0.95 0.8–0.98 Beta Miot et al.11 
CM patient (induction phase) 0.5 0.43–0.58 Beta Miot et al.11 
Stable with CM (maintenance phase) 0.8 0.68–0.92 Beta Miot et al.11 
Cryptococcus accuracy tests Sensitivity (%)/ CI (%)
Specificity 
(%)/ CI (%) Source
Serum





Temfack et al.21 
India ink 86.1 97.3





CI = confidence interval.
Table 1 - Values of procedures, treatments, medications, and tests included in the economic model and other parameters of the 
model. (cont.)
Assumptions
The parameter assumptions was based on prospective 
CRAG studies and Brazilian consensus4,17-23 with a 
cohort of HIV-infected patients with CD4 < 100 cells/uL. 
Primary outcomes were expected costs, DALYs, 
and incremental cost-effectiveness ratios (ICERs. 
CRAG-positive individuals (CRAG+) may be asymptomatic 
and eligible for the preventive treatment with fluconazole 
in the model. International studies were used11,17-19,24 the 
prevalence of cryptococcal antigenemia (CrAg+ in the 
absence of studies on Brazilian population’s quality of life 
for the outcomes described. 
The model did not incorporate the ART treatment7 
after using antifungals, the adverse effects resulting 
from amphotericin, and intracranial hypertension (CH) 
as a complication of CM. The use of amphotericin B 
deoxycholate (1 mg/kg/week) and other drugs to replace 
fluconazole was not considered. 
Economic model
Figure 1 presents a schematic representation of the 
transition states for CM screening and treatment, with two 
residual states where the patient dies or has predominantly 
negative CM symptoms. Data from the Vidal et al.5 a tertiary 
referral hospital to HIV-infected patients serving the São 
Paulo State, Brazil. All patients were >18 years old without 
prior cryptococcal meningitis, without clinical suspicion of 
cryptococcal meningitis, regardless of antiretroviral (ART 
were used to calibrate the model.
As CM and mortality progression depends on CD4 
levels, the target population had two PLHIV subgroups: 
CD4 ≤ 100 cells/mm3 and CD4 ≤ 200 cells/mm3. For each 
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subgroup, after screening, those who were CRAG+ undergo 
preemptive treatment. After this stage, these individuals 
may or may not progress to CM. Those who developed CM 
undergo treatment consisting of induction, consolidation 
and maintenance. After the end of the treatment, those who 
did not die progress to a state without CM.
All CRAG-negative individuals, considered without 
CM, could develop meningitis depending on their true 
or false negative condition. Those who have undergone 
preemptive treatment could also progress to a CM status 
at any time, just as anyone who had finished the in-hospital 
therapy and may have a relapsed or contracted CM again. 
Sensitivity analysis
Deterministic and probabilistic sensitivities analyzed 
uncertainties of the model. The discount rate varied from 
0% to 5%, and medical costs were estimated by values 
found in public purchasing bases. 
Patients’ utilities and average medical costs changed in 
a directly proportional manner. Medical costs are related 
to SUS’s services and showed similar results among 
patients, regardless of the therapeutic alternatives. A 
scatterplot was constructed in the probabilistic sensitivity 
analysis indicating the option that was most likely to be 
cost-effective.
Budget impact
The budgetary impact analysis employed the demand 
method25. The use of the CRAG-LFA diagnostic test in 
SUS was simulated for five years to screen for cryptococcus 
infection in PLHIV with CD4+ ≤ 200 cells/mm3. The 
BIA adopted the SUS perspective25. The price of the 
implemented technology was U$S 6 per test. The costs to 
assess the budgetary impact were as follows: screening –
U$S 6, preemptive treatment –U$S 277.8, and meningitis 
treatment –U$S 2,644.60 dollars. Table 1 shows the costs 
of the screening and treatments.
In 2021, the Brazilian population was 212,601,219 
inhabitants26. The HIV cases considered were the mean 
number of cases in the period from 2018 to 2020 reported 
to the Notifiable Diseases Information System (SINAN), 
declared in the Mortality Information System (SIM), 
and registered in the Control System for Laboratory 
Examinations of the National Network of CD4+/CD8+ 
Lymphocyte Count and HIV Viral Load (SISCEL)/Logistics 
Control System for Medicines (SICLOM)9.
RESULTS
For the effectiveness measured in years of life, 
the microsimulation estimated an incremental cost-
effectiveness ratio (ICER) that is shown in Table 2.
The cost-effectiveness analysis showed that the two 
tests, CRAG-LA and CRAG-LFA, are cost-effective, a 
superior performance in comparison with the India ink and 
the no evaluation scenario.
As the CRAG-LA and CRAG-LFA tests proved to be 
cost-effective, a deterministic univariate sensitivity analysis 
evaluated the accuracy of each of the tests, their sensitivities 
and specificities (Table 3). The results for sensitivity showed 
that both tests are no longer cost-effective for values below 
0.975. For specificity, this response occurs for CRAG-LFA 
Figure 1 - Schematic model of transition states for the screening of cryptococcal meningitis (CM) in asymptomatic PLHIV with 
≤ 200 cells/mm³. CM = Cryptococcal meningitis; CRAG = Cryptococcal antigen.
Vianna and Mosegui
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above 0.9 and for CRAG-LA with values around 0.99. The 
price of CRAG-LA was changed to assess its impact in the 
result. For the same price as CRAG-LFA, of U$S 6 per test, 
the alternative to use CRAG-LA was superior. 
The probabilistic sensitivity analysis between 
CRAG-LFA and CRAG-LA, although pointing to a high 
agreement between the two tests, indicated the superiority 
of CRAG-LFA (Figure 2). In approximately 38% of the 
cases, this test was superior to the CRAG-LA.
Budget impact 
We would have a total cost for a cohort of 45,000 patients 
with the hypothesis of all of them treated for meningitis of 
approximately U$S 34.8 million dollars for five years 
without screening. Using the measured demand method 
and a five-year time horizon, an assumed initial market 
share of 20% for CRAG-LFA, with annual increments 
of the same amount, reaching 100% in the fifth year, the 
estimated budget impact resulting from the incorporation 
Table 2 - Incremental cost-effectiveness ratio in years of life and QALY of screening strategies for asymptomatic cryptococcus 
infections in PLHIV with CD4 ≤ 200 cells/mm³. 
Strategy Cost (U$S) ∆ Cost Eff. 
(years of life )
∆ Eff. ICER 
(U$S/ years of life)
Comments
CRAG-LA 126.65 0.000 4.718 0.000 0.000
CRAG-LFA 126.90 1.255 4.721 0.003 73.37
India ink 136.85 49.742 4.705 -0.016 606.60 (was superior )
No intervention 172.27 226.873 4.603 -0.118 384.57 (was superior )
Cost (U$S) ) ∆ Cost Eff. (QALY) ∆ Eff. ICER (U$S/QALY) Comments
CRAG-LA 126.65 0.000 4.449 0.000 0.000
CRAG-LFA 126.90 1.255 4.453 0.004 66.92
India ink 136.85 49.742 4.435 -0.018 - 553.32 (was superior )
No intervention 172.27 226.873 4.323 -0.129 - 350.79 (was superior )
∆ = incremental difference; Eff. = effectiveness.
Table 3 - Univariate sensitivity analysis for the cost of the CRAG-LA. 
Strategy Cost (U$S) Eff. ∆ Cost ∆ Eff. ICER 
(U$S/ years of life)
Comments
Tracking Cost of CRAG-LA U$S 5.8 
CRAG-LA 126.65 4.718 0.000 0.000 0.000
CRAG-LFA 126.90 4.721 1.255 0.003 73.36 
India ink 136.85 4.705 49.742 -0.016 - 606.60 (was superior)
No intervention 172.27 4.603 226.873 -0.118 - 384.57 (was superior )
Tracking Cost of CRAG-LA U$S 6.00 
CRAG-LFA 126.90 4.721 0.000 0.000 0.000
CRAG-LA 127.03 4.718 0.645 -0.003 - 37.70 (was superior )
India´ ink 136.85 4.705 49.742 -0.016 - 606.60 (was superior )
No intervention 172.27 4.603 226.873 -0.118 - 384.57 (was superior )
∆ = incremental difference; Eff = effectiveness. Costs in US dollars considering that 1 U$S dollar equals 5 reais (the Brazilian current 
money). Effectiveness in years of life. 
Figure 2 - Probabilistic sensitivity analysis: CRAG-LFA versus 
CRAG-LA. 
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of the test would have an additional cost of approximately 
U$S 10.5 million dollars. For comparison, the budgetary 
impact of 100% adoption of screening for asymptomatic 
PLHIV CD4 ≤ 200 cells/mm3 is a five-year cost savings of 
U$S 11 million dollars in this context. 
DISCUSSION
The diagnosis and management of cryptococcosis 
and its outcomes are structural problems in Brazil1,4,5 
que fazem parte do complexo C. neoformans. Com o 
aparecimento da AIDS, houve expressivo aumento na 
incidência da criptococose. Posteriormente, o uso de 
antifúngicos profiláticos e a introdução da HAART levaram 
à redução desta incidência. Objetivamos determinar o 
perfil epidemiológico da meningite criptocócica no Estado 
do Rio de Janeiro no período de 1994 a 2004, com base 
nos dados da Assessoria de Meningite, setor do Centro de 
Vigilância Epidemiológica da SSE-RJ e, também, avaliar 
em que medida o perfil epidemiológico disponível no 
sistema nacional (SINAN. Our study suggests that, for 
PLHIV with CD4 ≤ 200 cells/mm3, the incorporation of 
CRAG-LFA or CRAG-LA in the patients’ screening would 
be advantageous compared to no screening and the India 
ink test. Our model projects a reduction in mortality due to 
CM in PLHIV CRAG+ CD4 ≤ 200 cells/mm3 by 15%, while 
costs for 1,000 patients would decrease by US$ 11 million 
dollars in five years compared to no screening.
Ramachandran et al.18 conducted a study similar to 
ours in Uganda, Africa. The authors assessed the costs and 
cost-effectiveness of implementing a CRAG screening 
for PLHIV in comparison with the usual practice. The 
CRAG screening was considered highly cost-effective 
and was associated with an ICER of US$ 6.14 per avoided 
DALY compared to no screening. The implementation 
cost of CRAG screening was of an additional US$1.52 per 
person and resulted in a 40% relative reduction in disease-
associated mortality. The probabilistic sensitivity analysis 
showed that the CRAG screening was cost-effective in 
100% of the scenarios. A secondary analysis projected a 
total cost of US$651.454 for the 100% implementation 
of the screening in the country, preventing 1,228 deaths 
compared to no screening.
Another study carried out in Cambodia27 one 
time systematic serum cryptococcal antigen (CRAG 
evaluated the cost-effectiveness of three alternative 
strategies for preventing cryptococcal infection in 
HIV-infected patients. Opportunistic cryptococcal 
infection is endemic in Cambodia and corresponds 
to a significant public health burden in PLHIV 
there and in Brazil. Over a one-year horizon, the 
systematic CRAG screening (for targeted treatment of 
positive cases) in patients with CD4 ≤ 100 cells/mm3 
is more cost-effective for preventing cryptococcosis than 
the systematic primary prophylaxis strategy.
Tenforde et al.28 made a cost-effective model of CRAG 
screening for CRAG+, treatment-naïve patients with 
CD4 ≤ 100 cells/mm3 and CRAG+ CD4 ≤ 100 cells/mm3 
with previous experience of ART in Botswana. The authors 
estimated that of 650,000 samples submitted to the CD4 
test annually, 16,364 would have CD4 ≤ 100 cells/mm3 
and would undergo a CRAG test, and 70% of patients 
reporting previous experience with ART at the time of 
screening. CRAG screening and preventive treatment 
in CD4 treatment-naïve patients with ≤ 100 cells/mm3 
prevented 20% of MC-related deaths at the cost of US$2 per 
avoided DALY. The expansion of the preemptive treatment, 
including patients with previous ART experience and CD4 ≤ 
100 cells/mm3, would generated 55 additional cost-avoided 
deaths with respect to no screening. 
The results of the present study deserve to be 
analyzed carefully. Some limitations are inherent to the 
modeling process, which can have oversimplified the 
disease’s progression due to differences in real-world 
circumstances and the use of more than one treatment, 
disease complications and adverse drug effects. Different 
sources of international data were the basis for estimating 
the transition probability values2,8,16,20 and we aimed 
to provide an updated estimate of global incidence of 
HIV-associated cryptococcal disease. Methods We used 
2014 Joint UN Programme on HIV and AIDS estimates 
of adults (aged >15 years. In the sensitivity analysis, 
these variables did not affect the results. We have also 
considered that any CM complication would lead to 
hospitalization or death, which may not be accurate in 
all cases. The model did not include effects other than 
meningitis caused by cryptococcal infections and the 
adverse effects of treatment.
Unit costs calculated from SIGTAP13 may be 
underestimated. Two of the technologies used for 
comparisons had no prices indicated in the BPS12, and the 
2016 AMB table was used15, which may be out of date. 
Still, as the CRAG-LFA was superior than the other two 
tests, these prices have little influence on the result. In this 
analysis, we assumed equal hospitalization days for patients 
who underwent screening with any of the technologies. 
Because of the lower accuracy of a given method, the 
duration of admission, risk of readmission, and risk of 
complications that could prolong hospitalization therefore 
increasing hospital care costs and duration. The cheapest 
combination corresponding to the use of fluconazole was 
adopted on the list of CMED29 at a maximum price to the 
Vianna and Mosegui
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consumer instead of the government’s purchase price. 
Finally, the intangible costs of using each technology 
have not been calculated. The result of the CRAG-LFA 
test from blood collection can be obtained in 10 minutes. 
However, CRAG-LA requires a lumbar puncture and a 
medical follow-up. 
CONCLUSION
An economic evaluation of the Monte Carlo 
microsimulation estimated the main costs and consequences 
of the cost-effectiveness analysis and budgetary impact of 
implementing the CRAG-LFA test for the screening of 
cryptococcus infection in PLHIV with CD4+ ≤ 200 cells/mm3 
in comparison with the CRAG-LA, the India ink, and no 
screening as the reference, from the perspective of the 
Brazilian Unified Health System. 
Given the results of this study, the CRAG-LFA 
and CRAG-LA tests are potentially cost-effective to 
track cryptococcal infections, preventing mortality 
related to cryptococcal meningitis in PLHIV with 
CD4 ≤ 200 cells/mm3. India ink and no intervention were 
inferior strategies. According to the results of the model and 
the sensitivity analysis, CRAG screening for PLWH with 
CD4+ ≤ 200 cells/mm3 represents an excellent opportunity 
to save money with the potential to prevent CM and reduce 
the corresponding mortality in Brazil. The BIA showed 
that for a cohort of 45,000 patients without screening, we 
would have a total cost of approximately U$S 34.8 million 
dollars in five years. The budgetary impact of the 100% 
adoption of screening in PLHIV CD4 ≤ 200 cells/mm3 and 
asymptomatic CM infections would save U$S 11 million 
dollars in five years.
Finally, a review of epidemiology researches on the 
consequences of cryptococcal screening in asymptomatic 
patients highlighted a significant knowledge gap that 
exist worldwide, especially in Brazil. Now, the paucity 
of parameters is the main barrier for the development 
of simulation models that are more compatible with the 
knowledge accumulated in laboratory practice. 
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